Japan is facing a supply shortage of GLP-1 receptor antagonists for type 2 diabetes due to their off-label use as diet drugs, prompting the main manufacturers to restrict supplies and calls for their use only in officially approved indications.
Japan Faces GLP-1 Shortage As Off-Label Diet Use Surges
Grey Areas Between Regulations
Despite repeated warnings by regulatory authorities and physicians’ associations, the demand for easy diet aids is impacting the supply of GLP-1 receptor antagonists in Japan.
More from Japan
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.
• By
A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.
More from Asia
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.
• By
The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.